Primera especialidad

Permanent URI for this communityhttps://hdl.handle.net/20.500.14595/820

Browse

Now showing 1 - 2 of 2

Exploring psilocybin’s role in mental health and palliative medicine: a path to improved well-being
(Expert Opinion on Emerging Drugs, 2025-04-25) Maria-Alejandra Umbacia, Marta Ximena Leon, Jose-Manuel Quintero, LinaMaria Castro, Veronica Paez, Seetal Dodd & Rosa-Helena Bustos
ABSTRACT Introduction: Although long known for their psychoactive effects, psychedelic drugs have only recently been investigated for medicinal use. Psilocybin has attracted the greatest interest with studies suggesting that it may be a useful agent in psychiatry and in palliative care. Areas covered: Clinical trials that included psilocybin were searched in PubMed, Embase, and ClinicalTrials.gov, demonstrating that adult psychiatry and palliative care are the medical fields that show the greatest interest in psilocybin treatment. Expert opinion: Psilocybin is a powerful drug that needs to be used with caution but may benefit some patients, including when other options have failed. It is best evidenced in treatment resistant depression and in palliative care, where patients are usually treated in specialist care centers. It has a novel mechanism of action, targeting the 5HT2A receptor, and can show rapid onset of action. There are many questions regarding its use that remain to be clarified, including its efficacy for other indications and its role as adjunctive treatment in psychotherapy. The psychoactive, or psychedelic effects are well documented, but their clinical importance is disputed.
Guided imagery for symptom management of patients with life-limiting illnesses: A systematic review of randomized controlled trials.
(Journal of Palliative Medicine, 2024-06-22) Juan Esteban Correa-Morales; Nidia Mantilla-Manosalva; Ximena Rodriguez-Cardona; Lennis Jazmin Bedoya-Muñoz; Bibiana Florez-Vargas; Martha Ximena Leon; Sara Giraldo-Moreno; Omar Fernando Gomezese; Natalia Salamanca-Ballen
Patients with life-limiting illnesses receiving palliative care have a high symptom burden that can be challenging to manage. Guided imagery, an alternative therapy in which patients are induced to picture mental images with sensory components, has proven in quasi-experimental studies to be effective as a complementary therapy for symptom management. Objective: To systematically review randomized controlled trials that report evidence of guided imagery for symptom management in patients with life-limiting illnesses. Methods: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline was followed for this review and the search strategy was applied in Medline, CINHAL, and Web of Science. The quality of the articles was evaluated using the Cochrane Collaboration’s Risk-of-Bias Tool 2 (RoB 2). The results are presented using the Guidance on the Conduct of Narrative Synthesis in Systematic Reviews. Results: A total of 8822 studies were initially identified through the search strategy, but after applying exclusion criteria, 24 randomized controlled trials were included in this review. The quality assessment revealed that 11 studies had a high risk of bias, 11 had some concerns, and 2 had a low risk of bias. Out of the 24 included studies, 14 evaluated oncological diagnosis, while the remaining 9 focused on non-oncological diagnoses across 6 different diseases. Guided imagery was found to be effective in managing symptoms in 20 out of the 24 studies. Regardless of the disease stage, patients who received guided imagery experienced relief from anxiety, depression, pain, nausea, vomiting, sleep disturbances, and fatigue. Conclusion: Guided imagery therapy has shown promising results regarding symptom management in palliative care patients with life-limiting illnesses.

Browse

Browsing Primera especialidad by Subject "depression"